Jacobson Center for Clinical & Translational Research

Main Menu

/research/

Additional Information

 

Contact Us

Rheumatology Research

Study Title:  A Phase 2, Proof-of-Concept, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease (Identifier: NCT01559129)

Study Purpose:  The purpose of this first study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of pomalidomide (CC-4047) in the treatment of subjects with diffuse cutaneous systemic sclerosis with interstitial lung disease.

Principal Investigator: Bashar Kahaleh, M.D.

Study Coordinator: Stephanie J. Smiddy, RN, for more information, please contact 419.383.6921. Also see www.sclerodermastudy.com


Study Title:  Pulmonary Arterial Hypertension (PAH) in scleroderma patents Quality Enhancement Research Initiative (QuERI) Extension Program. (Identifier: NCT01389206)

Study Purpose:  This program intends to improve the management of pulmonary arterial hypertension (PAH) patients through an evidence-based approach aimed at achieving optimal World Health Organization (WHO) functional class (FC): 1. Improving FC III & IV patients to FC II, 2. Improving FC II patients to FC I, and 3. Maintaining FC II & FC I patients.

Principal Investigator: Bashar Kahaleh, M.D.

Study Coordinator: Stephanie J. Smiddy, RN, for more information, please contact 419.383.6921.


 

 

Last Updated: 11/6/14